Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients

Hematological Oncology

Volumn 27, Issue 3, 2009, Pages 148-153

  Breccia, Massimo ^a   Frustaci, Anna Maria ^a   Cannella, Laura ^a   Stefanizzi, Caterina ^a   Latagliata, Roberto ^a   Cartoni, Claudio ^a   Diverio, Daniela ^a   Guarini, Anna ^a   Nanni, Mauro ^a   Rago, Angela ^a   Cimino, Giuseppe ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute myeloid leukaemia; Comorbidities; Elderly; FLT3 abnormalities

Indexed keywords

CD135 ANTIGEN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; HYDROXYUREA; MITOXANTRONE; VINDESINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; DEATH; ELDERLY CARE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; LEUKOCYTOSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTOSIS; MALE; MULTIVARIATE ANALYSIS; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 70349349621     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.889     Document Type: Article

References (30)

1. Hiddemann W, Kern W, Schoch C, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol 1999; 17: 3569-3576. (Pubitemid 29517929)
2. Stone RM. The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin 2002; 52: 363-371. (Pubitemid 35446607)
3. Schaich M. Elderly acute myeloid leukemia: patients are not all the same. Haematologica 2004; 89: 261-263. (Pubitemid 38788405)
4. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89: 3323-3329. (Pubitemid 27229818)
5. Willman CL. Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR1). Leukemia 1996; 10 (Suppl 1): S33-35.
6. Pinto A, Zagonel V, Ferrara F. Acute myeloid leukemia in the elderly: biology and therapeutic strategies. Crit Rev Oncol Hematol 2001; 39: 275-287. (Pubitemid 32750296)
7. Wahlin A, Markevarn B, Golovleva I, Nilsson M. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol 2001; 115: 25-33. (Pubitemid 32995089)
8. Wedding U, Bokemeyer C, Meran JG. Working Group Geriatric Oncology of the German Society for Haematology and Oncology (DGHO), Austrian Society for Haematology and Oncology (OGHO), German Society for Geriatrics (DGG). Elderly patients with acute myeloid leukaemia: characteristics in biology, patients and treatment. Recommendations of the Working Group Geriatric Oncology of the German Society for Haematology and Oncology (DGHO), the Austrian Society for Haematology and Oncology (OGHO) and the German Society for Geriatrics (DGG). Onkologie 2004; 27: 72-82.
9. Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Cron Dis 1970; 23: 455-468.
10. Birim O, Kappetein AP, Bogers AJJC. Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer. Eur J Cardiothorac Surg 2005; 28: 759-762. (Pubitemid 41539333)
11. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919. (Pubitemid 41510773)
12. Etienne A, Esterni B, Charbonnier A, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukaemia. Cancer 2007; 109: 1376-1383. (Pubitemid 46466565)
13. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451-458.
14. Shaw MT. The cytochemistry of acute leukemia: a diagnostic and prognostic evaluation. Semin Oncol 1976; 3: 219-228.
15. San Miguel JF, Martinez A, Macedo A, et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997; 90: 2465-2470. (Pubitemid 27392732)
16. International Standing Committee on Human Cytogenetic Nomenclature. In An International System for Human Cytogenetic Nomenclature, Mittelman F (ed). S. Karger AG: Basel, Switzerland, 1995.
17. Grimwade D, Walker H, Harrison G, et al. Medical Research Council Adult Leukemia Working Party. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312-1320.
18. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidium thiocyanate-phenol chloroform extraction. Annal Biochem 1987; 162: 156-159.
19. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RTPCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-1928.
20. Noguera NI, Breccia M, Divona M, et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia 2002; 16: 2185-2189. (Pubitemid 35331832)
21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383. (Pubitemid 17055592)
22. Dombret H, Malfuson JV, Etienne A, et al. Are comorbidity scores useful decision making tools for intensive chemotherapy in elderly patients with acute myeloid leukaemia? Haematologica 2007; 92(suppl 2): abst. 55.
23. Amadori S, Suciu S, Willemze R, et al. EORTC leukemia group; GIMEMA leukemia group. Sequential administration of gentuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica 2004; 89: 950-956.
24. Estey EH. How I treat older patients with AML. Blood 2000; 96: 1670-1673. (Pubitemid 30661044)
25. De Lima M, Ghaddar H, Pierce S, Estey EH. Treatment of newly diagnosed acute myelogenous leukaemia in patients aged 80 years and above. Br J Haematol 1996; 93: 89-95. (Pubitemid 26132390)
26. Vey N, Coso D, Bardou VJ. The benefit of induction chemotherapy in patients age > or = 75 years. Cancer 2004; 101: 325-331.
27. Pinto A, Zagonel V, Ferrara F. Acute myeloid leukaemia in the elderly: biology and therapeutic strategies. Crit Rev Oncol Hematol 2001; 39: 275-287. (Pubitemid 32750296)
28. Chen CC, Yang CF, Yang MK, et al. Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukaemia. Ann Oncol 2005; 16: 1366-1373.
29. Stirewalt DL, Kopecky KJ, Meshinchi S, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001; 97: 3589-3595.
30. Andersson A, Johansson B, Lassen C, Mitelman F, Billstrom R, Fioretos T. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients. Eur J Haematol 2004; 72: 307-313. (Pubitemid 38520727)